Allergen Immunotherapy in the Era of SARS-CoV-2
- 10 December 2020
- journal article
- editorial
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 30 (6), 459-461
- https://doi.org/10.18176/jiaci.0568
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Risk factors for severity and mortality in adult COVID-19 inpatients in WuhanJournal of Allergy and Clinical Immunology, 2020
- The safety of carbamylated monomeric allergoids for sublingual immunotherapy. Data from a pharmacovigilance studyImmunotherapy, 2020
- Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkersJournal of Allergy and Clinical Immunology, 2017
- Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illnessJournal of Allergy and Clinical Immunology, 2017
- EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitisAllergy, 2017
- Allergen immunotherapy for allergic asthma: A systematic review and meta‐analysisAllergy, 2017
- Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United StatesThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic AsthmaJAMA, 2016
- A novel approach in allergen-specific immunotherapy: Combination of sublingual and subcutaneous routesJournal of Allergy and Clinical Immunology, 2011